Testing a combination drug for psoriasis and high cholesterol
Part of Hormones & metabolism, Skin clinical trials.
This trial tests whether a combination of two drugs (vunakizumab and recaticimab) can help people who have both moderate-to-severe plaque psoriasis and high cholesterol. It aims to see if the treatment is safe and effective for both conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with plaque psoriasis (the most common type).
- Your psoriasis covers at least 10% of your body or is rated as moderate to severe by your doctor.
- You have high cholesterol, with LDL ('bad') cholesterol between 2.6 and 4.9 mmol/L, and triglycerides (another type of fat) below 5.6 mmol/L.
- You have not had certain treatments for psoriasis or cholesterol within the last few weeks to months (like strong oral medications, injections, or light therapy).
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
This study compares two medications for psoriasis (deucravacitinib and ustekinumab) over a long period. It's designed for people with moderate-to-severe psoriasis who also have certain risk factors for heart disease, like high blood pressure or diabetes.
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
This study tests an investigational tablet called ASC50 for plaque psoriasis. It aims to see if it is safe and works well for people with this skin condition.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.